Geode Capital Management LLC boosted its stake in ABIOMED, Inc. (NASDAQ:ABMD) by 3.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 360,507 shares of the medical equipment provider’s stock after buying an additional 10,862 shares during the period. Geode Capital Management LLC owned 0.81% of ABIOMED worth $67,562,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of ABMD. Crow Point Partners LLC acquired a new stake in ABIOMED in the fourth quarter worth $120,000. Cerebellum GP LLC acquired a new stake in ABIOMED in the fourth quarter worth $127,000. SeaCrest Wealth Management LLC acquired a new stake in ABIOMED in the fourth quarter worth $183,000. Sigma Planning Corp acquired a new stake in ABIOMED in the third quarter worth $206,000. Finally, Advisor Partners LLC acquired a new stake in ABIOMED in the fourth quarter worth $209,000. 88.42% of the stock is currently owned by hedge funds and other institutional investors.
In other news, VP Andrew J. Greenfield sold 20,000 shares of the firm’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $270.36, for a total transaction of $5,407,200.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 7.00% of the stock is currently owned by company insiders.
ABIOMED, Inc. (NASDAQ:ABMD) opened at $293.17 on Wednesday. The company has a market capitalization of $13,050.44, a price-to-earnings ratio of 148.07, a PEG ratio of 4.06 and a beta of 0.25. ABIOMED, Inc. has a fifty-two week low of $117.36 and a fifty-two week high of $304.28.
ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.50 by $0.20. The company had revenue of $154.00 million for the quarter, compared to analyst estimates of $154.00 million. ABIOMED had a return on equity of 15.54% and a net margin of 16.58%. The company’s quarterly revenue was up 34.9% compared to the same quarter last year. During the same period last year, the company earned $0.34 earnings per share. research analysts anticipate that ABIOMED, Inc. will post 2.3 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This report was first posted by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/03/14/geode-capital-management-llc-has-67-56-million-holdings-in-abiomed-inc-abmd.html.
ABIOMED Company Profile
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.